NAC Supplementation Shows Promise in Reducing Preterm Birth Risks

New research suggests that antenatal N-acetylcysteine (NAC) supplementation could significantly improve outcomes for pregnant women at risk of preterm birth. The findings highlight its potential to reduce neonatal complications and maternal infections when given in controlled doses. Scientists now call for larger trials to confirm these benefits across different populations. The study focused on pregnant women facing imminent preterm labour. Results showed that NAC, an antioxidant, lowered the risk of complications in newborns. It also reduced maternal infections and inflammation without harming fetal growth or pregnancy duration.

NAC works by boosting glutathione levels and adjusting NF-κB pathways, which help protect cells. Researchers stressed the importance of early identification in high-risk pregnancies to maximise its effects. They also noted that combining NAC with existing treatments, such as corticosteroids and tocolytics, could create a more effective prevention strategy. The findings suggest broader applications for NAC in obstetrics. However, experts warn that more multi-centre trials are needed to confirm its safety and efficacy in varied clinical settings. The study further recommended using both biochemical tests and clinical outcomes to assess such therapies thoroughly.

If validated, NAC supplementation could reduce the global impact of preterm birth, cutting disability rates and healthcare costs. Further research will determine whether it can be integrated into standard care for high-risk pregnancies. For now, the results offer a promising step toward better maternal and neonatal health.